文献速递青光眼

激光治疗青光眼与高眼压试验(LIGHT)中国随机对照试验:设计与基线特征

Laser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China - A Randomized Controlled Trial: Design and Baseline Characteristics.
PubMed 文献 · Am J Ophthalmol · 2021-05-02

该研究为在中国中山眼科中心开展的非盲、单中心、实用性随机对照试验,共纳入771例初诊原发性开角型青光眼(POAG,622例)或高眼压症(OHT,149例)患者,随机分入选择性激光小梁成形术(SLT)首选组或药物首选组,主要结局为健康相关生活质量(HRQL)。基线显示POAG患者平均年龄49.8岁、OHT患者38.8岁,POAG眼 median 眼压20 mmHg、OHT眼24 mmHg,POAG中央角膜厚度较OHT薄。与英国LiGHT试验参与者相比,本试验参与者更年轻、更近视且视野缺损更严重。

要点

  • 中国LiGHT试验随机分组比较SLT首选与药物首选的健康经济学结局。
  • 基线POAG眼 median 眼压20 mmHg,OHT眼24 mmHg。
  • 与英国LiGHT相比,本试验患者更年轻、更近视、视野缺损更重。

核心结论

  • 该试验旨在评估SLT作为一线治疗在中国POAG或OHT患者中是否较药物治疗提供更优的经济学和健康相关生活质量结局。

研究设计与样本

  • LiGHT China试验为非盲、单中心、实用性随机对照试验。
  • 2015年3月至2019年1月在中山眼科中心共纳入771例初诊患者,其中POAG 622例、OHT 149例。
  • 受试者随机分入SLT-1st组(必要时后续药物、手术)或Medicine-1st组(必要时后续手术)。

主要发现

  • POAG患者平均年龄49.8岁,OHT患者38.8岁。
  • 1,105只POAG眼 median 眼压为20 mmHg,271只OHT眼为24 mmHg。
  • POAG眼中央角膜厚度(CCT)为536 µm,薄于OHT眼的545 µm。
  • POAG眼视野 median 平均偏差为-4.2 dB;OHT眼 median 屈光不正为-1.5 D,POAG眼为-1.25 D。
  • POAG与OHT患者在GUI、GSS和VF-14基线评分上无差异;EQ-5D-5L差异为0.024。

关键数值与推荐

  • 主要结局为健康相关生活质量(HRQL)。
  • 次要结局包括临床结局、费用、成本效果、青光眼效用指数(GUI)、青光眼症状量表(GSS)、视觉功能及安全性。

临床怎么用

  • 该试验设计为在中国临床实践中评估SLT作为POAG或OHT一线治疗的经济性和生活质量影响提供随机对照证据。
  • 基线特征提示中国LiGHT试验人群与英国LiGHT试验人群存在差异,解读结果时需考虑人群可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To describe the baseline characteristics of a trial to evaluate whether selective laser trabeculoplasty (SLT), as a first-line treatment, provides superior economic and health-related quality of life outcomes to medical treatment in China. DESIGN: The LiGHT China trial is an unmasked, single-center, pragmatic, randomized controlled trial. METHODS: A total of 771 previously undiagnosed patients with primary open angle glaucoma (POAG, 622 patients) or ocular hypertension (OHT, 149 patients) at Zhongshan Ophthalmic Center were recruited from March 2015 to January 2019. Subjects were randomized to SLT-1st (followed by medication then surgery when required) or Medicine-1st (medication followed by surgery when required). The primary outcome was health-related quality of life (HRQL). The secondary outcomes were clinical outcomes, cost, cost-effectiveness, Glaucoma Utility Index, Glaucoma Symptom Scale, visual function, and safety. RESULTS: The mean age of POAG patients was 49.8 years and 38.8 years for OHT. The median intraocular pressure was 20 mm Hg for the 1,105 POAG eyes and 24 mm Hg for the 271 OHT eyes. POAG eyes had thinner central cornea thickness (CCT, 536 µm) than OHT eyes (545 µm). Median mean deviation of the visual field in POAG eyes was -4.2 dB. Median refractive error was -1.5 D for OHT eyes and -1.25 D for POAG eyes. There was no difference between POAG and OHT patients on baseline scores of GUI, GSS and VF-14. The difference between OHT and POAG on the EQ-5D-5L was 0.024. CONCLUSIONS: Compared with participants in the LiGHT UK trial, participants in this trial were younger, more myopic and had more severe visual field defects.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Yang Y, Jiang Y, Huang S, et al. Laser in Glaucoma and Ocular Hypertension Trial (LIGHT) in China - A Randomized Controlled Trial: Design and Baseline Characteristics. Am J Ophthalmol. 2021. PMID: 33951448. doi:10.1016/j.ajo.2021.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。